Literature DB >> 15882544

Resistant hypertension revisited: a comparison of two university-based cohorts.

Jay P Garg1, William J Elliott, Amy Folker, Munavvar Izhar, Henry R Black.   

Abstract

BACKGROUND: More than a decade ago, we found that a suboptimal medication regimen was the leading cause of resistant hypertension (RH) among patients referred to a tertiary care clinic. Since then, lower blood pressure (BP) goals have been recommended, suggesting that more patients may have RH. To assess whether the reasons for and treatment of RH have changed, we determined the frequency of various causes of resistance, the proportion of patients achieving goal BP, and the changes made in antihypertensive regimens.
METHODS: The charts of all new patients seen at the RUSH University Hypertension Center between January 1, 1993, and November 1, 2001, were reviewed for strict criteria for RH: 1) physician referral for uncontrolled hypertension; 2) BP > or =140/90 mmHg despite use of three antihypertensive drugs; and 3) at least one follow-up visit. Patients were followed-up until goal BP was achieved on two consecutive visits or their last visit or until March 2002.
RESULTS: Of 1281 patients, 141 met criteria for RH. A cause of resistance was found in 94% of cases, including the following: drug-related causes (58%); nonadherence (16%); psychological causes (9%); office resistance (ie, in-clinic BP readings that were higher than goal despite treatment with antihypertensive medications and despite normotensive BP outside of the clinic as demonstrated by 24-h ambulatory BP monitoring) (6%); and secondary hypertension (5%). Overall, 53% of patients had their BP controlled to <140/90 mmHg, largely from regimen optimization and intensification, proper use of diuretics, and on average 4.1 +/- 1 antihypertensive medications (3.7 +/- 0.9 on referral).
CONCLUSIONS: These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance. Goal BP was most commonly achieved after optimizing the diuretic regimen and increasing the number of medications, suggesting that physicians should use these measures to attain the recommended lower BP goals If goal BP is not reached, referral to a clinical hypertension specialist may be appropriate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882544     DOI: 10.1016/j.amjhyper.2004.11.021

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  71 in total

1.  Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care.

Authors:  Peter Hayes; Monica Casey; Liam G Glynn; Gerard J Molloy; Hannah Durand; Eoin O'Brien; Eamon Dolan; John Newell; Andrew W Murphy
Journal:  Br J Gen Pract       Date:  2018-05-08       Impact factor: 5.386

Review 2.  Resistant hypertension and aldosteronism.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

3.  The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Julie A Schmittdiel; P Michael Ho
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

Review 4.  Assessment and management of resistant hypertension.

Authors:  Raj S Padwal; Simon Rabkin; Nadia Khan
Journal:  CMAJ       Date:  2014-08-18       Impact factor: 8.262

5.  Resistant hypertension: do all definitions describe the same patients?

Authors:  L Boswell; J Pascual; A Oliveras
Journal:  J Hum Hypertens       Date:  2015-01-15       Impact factor: 3.012

Review 6.  Natriuretic Peptides as a Novel Target in Resistant Hypertension.

Authors:  Pratik Patel; Horng H Chen
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

7.  An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade.

Authors:  Scott Martin Vouri; Joseph S van Tuyl; Margaret A Olsen; Hong Xian; Mario Schootman
Journal:  J Am Pharm Assoc (2003)       Date:  2018-07-20

8.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 9.  [Epidemiology and etiology of therapy-resistant hypertension].

Authors:  C Schirpenbach; M Reincke
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

Review 10.  Resistant Hypertension Updated Guidelines.

Authors:  Irene Chernova; Namrata Krishnan
Journal:  Curr Cardiol Rep       Date:  2019-08-30       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.